(6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetic acid ethyl ester | 193470-41-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetic acid ethyl ester
• 英文别名: Ethyl (6-Methoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)acetate；3,4-Dihydro-6-methoxy-2(1H)-isoquinolineacetic acid ethyl ester；ethyl 2-(6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetate
• CAS: 193470-41-6
• 化学式: C₁₄H₁₉NO₃
• 分子量: 249.31
• InChiKey: LFBQTKDIOJICPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetic acid ethyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 2-(6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetic acid
  参考文献：
  名称：

  Synthesis and In Vitro Opioid Receptor Functional Antagonism of Analogues of the Selective Kappa Opioid Receptor Antagonist (3R)-7-Hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic)

  摘要：

  In previous structure-activity relationship (SAR) studies, we identified (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic, 1) as the first potent and selective K opioid receptor antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonist. In the present study, we report the synthesis and in vitro opioid receptor functional antagonism of a number of analogues of 1 using a [S-35]GTP gamma S binding assay. The results from the studies better define the pharmacophore for this class of K opioid receptor antagonist and has identified new potent and selective kappa antagonist. (3R)-7-Hydroxy-N-[(1 S, 2S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-2-methylbutyl]-1,2,3,4tetrahydroisoquinoline-3-carboxamide (3) with a K-e value of 0.03 nM at the kappa receptor and 100- and 793-fold selectivity relative to the mu and delta receptors was the most potent and selective kappa opioid receptor antagonist identified.

  DOI：

  10.1021/jm701344b
• 作为产物：
  描述：

  6-甲氧基-3,4-二氢-1(2H)-异喹啉 在 氢化钾 作用下， 以 四氢呋喃 、 溴乙酸乙酯 为溶剂， 以86%的产率得到(6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetic acid ethyl ester
  参考文献：
  名称：

  Lactam derivatives as antiarrhythmic agents

  摘要：

  该公式的内酰胺衍生物，其中X为—C(═O)NR3′—，—NR3′C(═O)—，—C(═NCN)NR3′—，—NR3′C(═NCN)—，—CH2NR3′—，—CH(烷基)NR3′—，—CH(COO烷基)NR3′—，—CH(CH2OH)NR3′—，—C(CH2O烷基)—；R1为卤素，烷基，环烷基，烷基(环烷基)，芳基，(芳基)烷基，(芳基)烯基，(芳基)炔基，O-烷基，O-烯基，O-芳基，O-烷基(芳基)，O-烷基(杂环烷基)，COO-烷基，C)-烷基，CO-氨基，CO-取代氨基，烷基-CO-氨基，烷基-CO-取代氨基，NHCO-烷基，NHCO-芳基，NHCO-烷基(芳基)，NHCO-烷基(杂环烷基)，N(烷基)CO-烷基，N(烷基)CO-芳基，N(烷基)CO-杂环烷基，N(烷基)CO-烷基(芳基)，N(烷基)CO-烷基(杂环烷基)；R2为氢，烷基，卤素，芳基，(芳基)烷基，O-烷基，氨基，取代氨基；R3和R3′相同或不同，独立选择自氢，烷基或烷基(芳基)；R4可以与环烷基或氮键合，选择自氢，烷基，烯基，烷基(芳基)，烷基(杂环烷基)，环烷基，烷基(环烷基)，烷基-(氨基)，烷基-(取代氨基)，烷基-NHCO(烷基)，烷基-NHCO(芳基)，烷基-NHCO(杂环烷基)，烷基-NHCO(烷基芳基)，烷基-NHCO(烷基杂环烷基)；n为0至2的整数。这些化合物已被发现在心律失常的治疗中具有用途。

  公开号：

  US06262068B1

文献信息

• Vitronectin receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US06159964A1

  公开（公告）日：2000-12-12

  Compounds of formula (I) are disclosed, wherein: A is a fibrinogen antagonist template; W is a linking moiety of the form --(CHR.sup.g).sub.a --U--(CHR.sup.g).sub.b --V--; Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 are independently N or C--R.sup.y, provided that no more than one Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 is N; R' is H or C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 -alkyl or Ar--C.sub.0-6 alkyl; R.sup.g is H or C.sub.1-6 alkyl, Het-C.sub.0-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 alkyl or Ar--C.sub.0-6 alkyl; R.sup.k is R.sup.g, --C(O)R.sup.g or --C(O)OR.sup.g R.sup.i is H, C.sub.1-6 alkyl, Het-C.sub.0-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 alkyl, Ar--C.sub.0-6 alkyl, Het-C.sub.0-6 alkyl--U'--C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 alkyl--U'--C.sub.1-6 alkyl or Ar--C.sub.0-6 alkyl--U'--C.sub.1-6 alkyl; R.sup.y is H, halo, --OR.sup.g, --SR.sup.g, --CN, --NR.sup.g R.sup.k, --NO.sub.2, --CF.sub.3, CF.sub.3 S(O).sub.r, --CO.sub.2 R.sup.g, --COR.sup.g or --CONR.sup.g.sub.2, or C.sub.1-6 alkyl optionally substituted by halo, --OR.sup.g, --SR.sup.g, --CN, --NR.sup.8 R", --NO.sub.2, --CF.sub.3, R'S(O).sub.3 --, --CO.sub.2 R.sup.g, --COR.sup.g or --CONR.sup.g.sub.2 ; U and V are absent or CO, CR.sup.g.sub.2, C(.dbd.CR.sup.g.sub.2), S(O).sub.c, O, NR.sup.g, CR.sup.g OR.sup.g, CR.sup.g (OR.sup.k)CR.sup.g.sub.2, CR.sup.g.sub.7 CR.sup.g (OR.sup.k), C(O)CR.sup.g.sub.2, CR.sup.g.sub.2 C(O), CONR.sup.i, NR.sup.i CO, OC(O), C(O)O, OC(S), C(S)NR.sup.g, NR.sup.8 C(S), S(O.sub..sub.2 NR.sup.g, NR.sup.g S(O).sub.2 N.dbd.N, NR.sup.g NR.sup.g, NR.sup.g CR.sup.g.sub.2, NR.sup.g CR.sup.g.sub.2, CR.sup.g.sub.2 O, OCR.sup.g.sub.2, CR.sup.g .dbd.CR.sup.g, C.ident.C, Ar or Het; a is 0, 1 or 2; c is 0, 1 or 2; r is 0, 1 or 2; and u is 0 or 1; or pharmaceutically acceptable salts thereof, which are vitronectin receptor antagonists useful in the treatment of osteoporosis. ##STR1##

  公式（I）的化合物被披露，其中：A是一种纤维蛋白原拮抗剂模板；W是形式为--(CHR.sup.g).sub.a--U--(CHR.sup.g).sub.b--V--的连接基团；Q.sup.1、Q.sup.2、Q.sup.3和Q.sup.4独立地是N或C--R.sup.y，前提是Q.sup.1、Q.sup.2、Q.sup.3和Q.sup.4中不超过一个是N；R'是H或C.sub.1-6烷基，C.sub.3-7环烷基-C.sub.0-6-烷基或Ar--C.sub.0-6烷基；R.sup.g是H或C.sub.1-6烷基，Het-C.sub.0-6烷基，C.sub.3-7环烷基-C.sub.0-6烷基或Ar--C.sub.0-6烷基；R.sup.k是R.sup.g，--C(O)R.sup.g或--C(O)OR.sup.g；R.sup.i是H，C.sub.1-6烷基，Het-C.sub.0-6烷基，C.sub.3-7环烷基-C.sub.0-6烷基，Ar--C.sub.0-6烷基，Het-C.sub.0-6烷基--U'--C.sub.1-6烷基，C.sub.3-7环烷基-C.sub.0-6烷基--U'--C.sub.1-6烷基或Ar--C.sub.0-6烷基--U'--C.sub.1-6烷基；R.sup.y是H，卤素，--OR.sup.g，--SR.sup.g，--CN，--NR.sup.g R.sup.k，--NO.sub.2，--CF.sub.3，CF.sub.3 S(O).sub.r，--CO.sub.2 R.sup.g，--COR.sup.g或--CONR.sup.g.sub.2，或者C.sub.1-6烷基，可选择地被卤素，--OR.sup.g，--SR.sup.g，--CN，--NR.sup.8 R"，--NO.sub.2，--CF.sub.3，R'S(O).sub.3--，--CO.sub.2 R.sup.g，--COR.sup.g或--CONR.sup.g.sub.2取代；U和V不存在或为CO，CR.sup.g.sub.2，C(.dbd.CR.sup.g.sub.2)，S(O).sub.c，O，NR.sup.g，CR.sup.g OR.sup.g，CR.sup.g(OR.sup.k)CR.sup.g.sub.2，CR.sup.g.sub.7 CR.sup.g(OR.sup.k)，C(O)CR.sup.g.sub.2，CR.sup.g.sub.2 C(O)，CONR.sup.i，NR.sup.i CO，OC(O)，C(O)O，OC(S)，C(S)NR.sup.g，NR.sup.8 C(S)，S(O.sub..sub.2 NR.sup.g，NR.sup.g S(O).sub.2 N.dbd.N，NR.sup.g NR.sup.g，NR.sup.g CR.sup.g.sub.2，NR.sup.g CR.sup.g.sub.2，CR.sup.g.sub.2 O，OCR.sup.g.sub.2，CR.sup.g.dbd.CR.sup.g，C.ident.C，Ar或Het；a为0、1或2；c为0、1或2；r为0、1或2；u为0或1；或其药学上可接受的盐，用于治疗骨质疏松症的维龙蛋白受体拮抗剂。
• US6262068B1
  申请人：——

  公开号：US6262068B1

  公开（公告）日：2001-07-17
• US6664250B2
  申请人：——

  公开号：US6664250B2

  公开（公告）日：2003-12-16
• Lactam derivatives as antiarrhythmic agents
  申请人：Bristol-Myers Squibb Company

  公开号：US06262068B1

  公开（公告）日：2001-07-17

  Lactam derivatives of the formula where X is —C(═O)NR3′—, —NR3′C(═O)—, —C(═NCN)NR3′—, —NR3′C(═NCN)—, —CH2NR3′—, —CH(alkyl)NR3′—, —CH(COOalkyl)NR3′—, —CH(CH2OH)NR3′—, —C(CH2Oalkyl)—; R1 is halo, alkyl, cycloalkyl, alkyl(cycloalkyl), aryl, (aryl)alkyl, (aryl)alkenyl, (aryl)alkynyl, O-alkyl, O-alkenyl, O-aryl, O-alky(aryl), O-alkyl(heterocyclo), COO-alkyl, C)-alkyl, CO-amino, CO-substituted amino, alkyl-CO-amino, alkyl-CO-substituted amino, NHCO-alkyl, NHCO-aryl, NHCO-alkyl(aryl), NHCO-alkyl(heterocyclo), N(alkyl)CO-alkyl, N(alkyl)CO-aryl, N(alkyl)CO-heterocyclo, N(alkyl)CO-alkyl(aryl), N(alkyl)CO-alkyl(heterocyclo); R2 is hydrogen, alkyl, halo, aryl, (aryl)alkyl, O-alkyl, amino, substituted amino; R3 and R3′ are the same or different and are independently selected from hydrogen, alkyl or alkyl(aryl); R4 which can be bonded to a ring carbon or nitrogen, is selected from hydrogen, alkyl, alkenyl, alky(aryl), alkyl(heterocyclo), cycloalkyl, alkyl(cycloalkyl), alkyl-(amino), alkyl-(substituted amino), alkyl-NHCO(alkyl), alkyl-NHCO(aryl), alkyl-NHCO(heterocyclo), alkyl-NHCO(alkylaryl), alkyl-NHCO(alkylheterocyclo); and n is an integer of 0 to 2. These compounds have been found to be useful in the treatment of arrhythmia.

  该公式的内酰胺衍生物，其中X为—C(═O)NR3′—，—NR3′C(═O)—，—C(═NCN)NR3′—，—NR3′C(═NCN)—，—CH2NR3′—，—CH(烷基)NR3′—，—CH(COO烷基)NR3′—，—CH(CH2OH)NR3′—，—C(CH2O烷基)—；R1为卤素，烷基，环烷基，烷基(环烷基)，芳基，(芳基)烷基，(芳基)烯基，(芳基)炔基，O-烷基，O-烯基，O-芳基，O-烷基(芳基)，O-烷基(杂环烷基)，COO-烷基，C)-烷基，CO-氨基，CO-取代氨基，烷基-CO-氨基，烷基-CO-取代氨基，NHCO-烷基，NHCO-芳基，NHCO-烷基(芳基)，NHCO-烷基(杂环烷基)，N(烷基)CO-烷基，N(烷基)CO-芳基，N(烷基)CO-杂环烷基，N(烷基)CO-烷基(芳基)，N(烷基)CO-烷基(杂环烷基)；R2为氢，烷基，卤素，芳基，(芳基)烷基，O-烷基，氨基，取代氨基；R3和R3′相同或不同，独立选择自氢，烷基或烷基(芳基)；R4可以与环烷基或氮键合，选择自氢，烷基，烯基，烷基(芳基)，烷基(杂环烷基)，环烷基，烷基(环烷基)，烷基-(氨基)，烷基-(取代氨基)，烷基-NHCO(烷基)，烷基-NHCO(芳基)，烷基-NHCO(杂环烷基)，烷基-NHCO(烷基芳基)，烷基-NHCO(烷基杂环烷基)；n为0至2的整数。这些化合物已被发现在心律失常的治疗中具有用途。
• Synthesis and In Vitro Opioid Receptor Functional Antagonism of Analogues of the Selective Kappa Opioid Receptor Antagonist (3<i>R</i>)-7-Hydroxy-<i>N</i>-((1<i>S</i>)-1-{[(3<i>R</i>,4<i>R</i>)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic)
  作者：Tingwei Bill Cai、Zhou Zou、James B. Thomas、Larry Brieaddy、Hernán A. Navarro、F. Ivy Carroll

  DOI：10.1021/jm701344b

  日期：2008.3.1

  In previous structure-activity relationship (SAR) studies, we identified (3R)-7-hydroxy-N-((1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic, 1) as the first potent and selective K opioid receptor antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonist. In the present study, we report the synthesis and in vitro opioid receptor functional antagonism of a number of analogues of 1 using a [S-35]GTP gamma S binding assay. The results from the studies better define the pharmacophore for this class of K opioid receptor antagonist and has identified new potent and selective kappa antagonist. (3R)-7-Hydroxy-N-[(1 S, 2S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-2-methylbutyl]-1,2,3,4tetrahydroisoquinoline-3-carboxamide (3) with a K-e value of 0.03 nM at the kappa receptor and 100- and 793-fold selectivity relative to the mu and delta receptors was the most potent and selective kappa opioid receptor antagonist identified.